Viridian Therapeutics Company Leadership
| VRDN Stock | USD 18.13 1.07 6.27% |
Viridian Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Viridian Therapeutics suggests that virtually all insiders are extremely bullish. Viridian Therapeutics employs about 94 people. The company is managed by 21 executives with a total tenure of roughly 220 years, averaging almost 10.0 years of service per executive, having 4.48 employees per reported executive.
Viridian Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-09-27 | Thomas W Beetham | Acquired 5000 @ 23.41 | View | ||
| 2024-09-13 | Fairmount Funds Management Llc | Acquired 1600000 @ 18.75 | View | ||
| 2024-01-22 | Fairmount Funds Management Llc | Acquired 476190 @ 21 | View |
Monitoring Viridian Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Viridian |
Viridian Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Viridian Therapeutics' future performance. Based on our forecasts, it is anticipated that Viridian will maintain a workforce of about 90 employees by February 2025.Viridian Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3215) % which means that it has lost $0.3215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5188) %, meaning that it created substantial loss on money invested by shareholders. Viridian Therapeutics' management efficiency ratios could be used to measure how well Viridian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of January 2025, Return On Tangible Assets is likely to drop to -0.46. In addition to that, Return On Capital Employed is likely to grow to -0.6. At this time, Viridian Therapeutics' Total Assets are very stable compared to the past year. As of the 18th of January 2025, Non Currrent Assets Other is likely to grow to about 1 M, while Non Current Assets Total are likely to drop about 2.6 M.As of the 18th of January 2025, Common Stock Shares Outstanding is likely to grow to about 54 M, though Net Loss is likely to grow to (111 M).
Viridian Therapeutics Workforce Comparison
Viridian Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 4,384. Viridian Therapeutics holds roughly 94.0 in number of employees claiming about 2.14% of equities under Health Care industry.
Viridian Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viridian Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viridian Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Viridian Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.8333 | 5 | 6 | 844,048 | 597,858 |
| 2023-09-01 | 1.0 | 1 | 1 | 40,000 | 175,000 |
| 2023-06-01 | 1.0 | 10 | 10 | 93,796 | 19,593 |
| 2023-03-01 | 1.0769 | 14 | 13 | 1,779,343 | 354,887 |
| 2022-12-01 | 0.6364 | 7 | 11 | 42,904 | 84,308 |
| 2022-06-01 | 1.2 | 6 | 5 | 75,000 | 300,000 |
| 2022-03-01 | 0.8 | 4 | 5 | 570,000 | 60,000 |
| 2021-12-01 | 0.6667 | 2 | 3 | 748,935 | 118,913 |
| 2021-09-01 | 4.0 | 4 | 1 | 1,494,000 | 0.00 |
| 2020-12-01 | 3.5 | 14 | 4 | 5,581,867 | 13,751,079 |
| 2020-06-01 | 6.0 | 6 | 1 | 144,000 | 530,733 |
| 2020-03-01 | 4.0 | 4 | 1 | 930,249 | 11,249 |
| 2019-09-01 | 1.0 | 1 | 1 | 3,093 | 3,093 |
| 2018-09-01 | 1.0 | 1 | 1 | 29,530 | 29,530 |
| 2018-03-01 | 4.5 | 9 | 2 | 1,168,979 | 139,818 |
| 2017-03-01 | 0.4 | 12 | 30 | 743,980 | 1,080,613 |
| 2016-12-01 | 0.6 | 3 | 5 | 346,000 | 469,707 |
| 2016-09-01 | 0.5 | 1 | 2 | 23,000 | 33,484 |
| 2016-06-01 | 2.5 | 5 | 2 | 196,251 | 189,086 |
| 2016-03-01 | 1.5 | 3 | 2 | 424,252 | 178,520 |
| 2015-09-01 | 2.0 | 16 | 8 | 191,500 | 48,022 |
| 2015-06-01 | 0.5 | 2 | 4 | 497,008 | 662,886 |
Viridian Therapeutics Notable Stakeholders
A Viridian Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Viridian Therapeutics often face trade-offs trying to please all of them. Viridian Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Viridian Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MBA JD | President CEO | Profile | |
| Seth Harmon | Principal Accounting | Profile | |
| Anthony Casicano | Chief Officer | Profile | |
| Kristian MBA | Chief CFO | Profile | |
| Melissa Manno | Chief Officer | Profile | |
| Anthony Casciano | Chief Officer | Profile | |
| Jennifer JD | Chief Officer | Profile | |
| Eric Olson | CoFounder Board | Profile | |
| MBA MD | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Jonathan MBA | CEO, CoFounder | Profile | |
| Rob Henderson | Chief Officer | Profile | |
| Carrie MBA | Chief Officer | Profile | |
| John Jordan | Vice Communications | Profile | |
| Marvin Caruthers | CoFounder Member | Profile | |
| Shan Wu | Chief Officer | Profile | |
| Vahe Bedian | CoFounder Scientist | Profile | |
| Lara Meisner | Sr Counsel | Profile | |
| CMO MBA | Chief Officer | Profile | |
| Todd IRC | Sr Relations | Profile | |
| Helen Milton | Senior Assurance | Profile |
About Viridian Therapeutics Management Performance
The success or failure of an entity such as Viridian Therapeutics often depends on how effective the management is. Viridian Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Viridian management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Viridian management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.63) | (0.60) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.62) | (0.59) |
Viridian Therapeutics Workforce Analysis
Traditionally, organizations such as Viridian Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Viridian Therapeutics within its industry.Viridian Therapeutics Manpower Efficiency
Return on Viridian Therapeutics Manpower
| Revenue Per Employee | 3.3K | |
| Revenue Per Executive | 15K | |
| Net Loss Per Employee | 2.5M | |
| Net Loss Per Executive | 11.3M | |
| Working Capital Per Employee | 4.9M | |
| Working Capital Per Executive | 21.9M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.59) | Revenue Per Share | Quarterly Revenue Growth 0.194 | Return On Assets | Return On Equity |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.